Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Shares Issued: 2023-2025

Historic Shares Issued for Contineum Therapeutics (CTNM) over the last 2 years, with Jun 2025 value amounting to $243,000.

  • Contineum Therapeutics' Shares Issued fell 21.86% to $243,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $267,000, marking a year-over-year decrease of 52.74%. This contributed to the annual value of $108.2 million for FY2024, which is 67957.23% up from last year.
  • According to the latest figures from Q2 2025, Contineum Therapeutics' Shares Issued is $243,000, which was up 912.50% from $24,000 recorded in Q1 2025.
  • In the past 5 years, Contineum Therapeutics' Shares Issued registered a high of $108.1 million during Q4 2024, and its lowest value of -$108.1 million during Q3 2024.
  • Over the past 3 years, Contineum Therapeutics' median Shares Issued value was $66,000 (recorded in 2023), while the average stood at $85,900.
  • Examining YoY changes over the last 5 years, Contineum Therapeutics' Shares Issued showed a top increase of 216,026.00% in 2024 and a maximum decrease of 131,884.15% in 2024.
  • Contineum Therapeutics' Shares Issued (Quarterly) stood at $50,000 in 2023, then spiked by 216,026.00% to $108.1 million in 2024, then dropped by 21.86% to $243,000 in 2025.
  • Its last three reported values are $243,000 in Q2 2025, $24,000 for Q1 2025, and $108.1 million during Q4 2024.